Latanelb Comp. (Latanoprost, Timolol)

Latanelb Comp., a prostaglandin analog and beta‑blocker combination, is indicated for conditions that require reduction of intra‑ocular pressure.

• Open-angle glaucoma: reduces intra‑ocular pressure to slow disease progression.
• Ocular hypertension: lowers pressure to prevent conversion to glaucoma.
• Secondary glaucoma (e.g., pseudoexfoliative): provides pressure control when monotherapy is insufficient.

• Latanoprost increases uveoscleral outflow of aqueous humor by activating prostaglandin F receptors in the ciliary body, while timolol non‑selectively blocks beta‑adrenergic receptors in the ciliary epithelium, reducing aqueous humor production. The combined actions result in a synergistic decrease in intra‑ocular pressure.

Adverse reactions to Latanelb Comp. are primarily ocular but systemic effects can also occur.

Common Side Effects

• Eye irritation or burning sensation.
• Blurred vision.
• Redness of the conjunctiva.
• Increased eyelash growth.
• Darkening of the iris.
• Headache.

Serious or Rare Side Effects

• Severe allergic reaction (e.g., angioedema, anaphylaxis).
• Chest pain or shortness of breath indicating possible cardiac effects.
• Sudden loss of vision or severe eye pain.
• Persistent ocular inflammation.
• Systemic hypotension or bradycardia.

When prescribing Latanelb Comp., clinicians should consider several safety aspects.

• Monitor intra‑ocular pressure: assess response after initiation.
• Assess cardiovascular status: beta‑blocker may affect heart rate and blood pressure.
• Avoid use in patients with asthma or severe chronic obstructive pulmonary disease: non‑selective beta blockade can precipitate bronchospasm.
• Caution in patients with severe renal impairment: adjust monitoring as drug clearance may be altered.
• Use sterile technique: avoid contamination of the ophthalmic solution.
• Store at room temperature: keep in original container, protect from light and moisture.

Latanelb Comp. may interact with other medications; awareness of potential interactions is essential.

Major Interactions (Avoid)

• Non‑selective beta‑blockers (e.g., propranolol): additive bradycardia and hypotension.
• Calcium channel blockers (e.g., verapamil): increased risk of heart block.
• Other prostaglandin analog eye drops: additive ocular effects and irritation.

Moderate Interactions (Monitor Closely):\n- Sympathomimetics (e.g., epinephrine eye drops): reduced efficacy of timolol.

• Monoamine oxidase inhibitors: potential systemic cardiovascular interaction.
• Anticholinergic agents: may affect ocular dynamics and tear production.